海南海药股份有限公司 关于持股 5%以上股东部分股份被司法拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000566 证券简称：海南海药 公告编号：2025-058 特别提示 1、本次司法拍卖标的为公司持股 5%以上股东深圳市南方同正投资有限公司 （以下简称"南方同正"）所持海南海药股份有限公司（以下简称"公司"或"海 南海药"）已质押的 123,825,900 股股票，占其所持公司全部股份的 92.86%， 占公司总股本的 9.54%。 2、根据京东司法拍卖平台页面显示的拍卖结果，本次股份拍卖因在规定时 间内无人出价未能竞拍成功。 公司于 2025 年 8 月 23 日披露了《关于持股 5%以上股东部分股份被司法拍 卖的提示性公告》（公告编号：2025-051），湖北省武汉市中级人民法院（以下 简称"武汉中院"）于 2025 年 9 月 22 日 10 时至 2025 年 9 月 23 日 10 时 止在京东网（http://sifa.jd.com/2251）进行公开司法拍卖南方同正所持海南 海药已质押的 123,825,900 ...

Group 1 - The company Hainan Haiyao reported that as of September 10, 2025, the number of shareholders is 76,345 [2]

Group 1 - The pharmaceutical industry in China is undergoing significant changes, with a shift from a focus on prevention to innovation, driven by the "Three Medical Linkage" policy and new healthcare reforms [1] - Hainan Haiyao is adapting to the complex industry landscape by leveraging state-owned enterprise reform and scientific innovation to enhance its R&D capabilities for sustainable high-quality development [1] Group 2 - Hainan Haiyao has established a "1234" development strategy focusing on high-quality growth, emphasizing three major missions: "defense, emergency, and public welfare," while expanding its chemical drug sector and high-end medical device platform [2] - The company aims to become a leading manufacturer of anti-infection drugs in China and a globally influential high-end medical device manufacturer, with aspirations to be the largest producer of raw materials and intermediates in China [2] Group 3 - Hainan Haiyao has defined a comprehensive product pipeline with a "6523 product mix," including 6 types of formulations, 5 types of raw materials, 2 types of intermediates, and 3 types of traditional Chinese medicine products [3] - Since 2023, the company has initiated 22 product projects across various dosage forms, including sustained-release, oral solutions, capsules, and effervescent tablets, targeting conditions such as hyperlipidemia, epilepsy, and infections [3] - The company has successfully passed consistency evaluations for 18 products, including minocycline hydrochloride capsules, which is the first in China to achieve this, creating new profit growth points for future development [3] - Hainan Haiyao is enhancing technical innovation through collaborations with research institutions and universities, establishing joint laboratories to expedite the discovery and development of new drug candidates [3]

Group 1 - The company conducted an investor relations activity focusing on the progress of innovative drug research and development, overseas rights cooperation, resolution of industry competition, and layout in the health sector [2] - The company is currently conducting Phase IIa clinical trials for the innovative drug Painegabine, with 100% enrollment of the target 36 participants, and expects to unblind and read results by the end of 2025 [2] - The company has completed the Phase II clinical trial for Fluofenone and is preparing for Phase III clinical trials, with data expected to be read out by the end of this year [2] Group 2 - The company is actively seeking suitable partners for overseas rights cooperation for Painegabine [2] - The company is addressing industry competition commitments with a focus on resolution [2] - The company has partnered with AFT Pharmaceuticals from New Zealand to become the exclusive sales agent for five products and signed a strategic cooperation agreement with Malaysia's Aikang International Group to leverage the Hainan Free Trade Port policy [2] Group 3 - The company plans to focus on the neuropsychiatric field, introducing a long-acting injection of Paliperidone for schizophrenia treatment, and aims to develop a product cluster [2] - The company is enhancing its product pipeline in traditional Chinese medicine, focusing on gastrointestinal health products, and aims to expand overseas registration and sales [2] - The company is deepening collaborations with universities and research institutions to explore high-end formulations and international partnerships [2]

Group 1 - The core viewpoint of the article is that Hainan Haiyao (SZ 000566) has conducted an investor survey, providing insights into its business structure and financial performance [1] - As of the first half of 2025, Hainan Haiyao's revenue composition is as follows: 78.45% from pharmaceuticals, 18.6% from medical service fees, and 2.95% from other businesses [1] - The current market capitalization of Hainan Haiyao is 7.7 billion yuan [1]

Clinical Trials and Drug Development - The company is conducting Phase IIa clinical trials for the drug Paenagabin, with a target enrollment of 36 cases, which has been fully achieved at a 100% completion rate. Preliminary data shows promising therapeutic effects [2][3] - The Phase II data for Paenagabin is expected to be unblinded and results read out by the end of 2025 [2][3] - The Phase II clinical research for another drug, Fluorofenone, has completed subject enrollment and data cleaning, with results expected to be revealed by the end of this year [3][4] - Preparations for the Phase III clinical trials of Fluorofenone are underway, anticipated to start between the end of this year and early next year [3][4] Market Expansion and Partnerships - The company is actively seeking international partners for the commercialization of innovative drugs, with future expansion dependent on the Phase II clinical results of Paenagabin [3][4] - A strategic cooperation agreement has been signed with Malaysia's Aikang International Group to introduce high-quality health products and promote traditional Chinese medicine products in the Malaysian market [3][4] Product Development and Focus Areas - The company plans to focus on the neuropsychiatric field, introducing a long-acting injection for the treatment of schizophrenia, thereby forming a product cluster in this area [4] - The company aims to expand its gastrointestinal product line, particularly the Gut Health series, targeting grassroots medical institutions and increasing user base [4] - There is a commitment to deepen collaborations with universities and research institutions to enhance competitiveness in high-end formulations [4] Risk Management - There are uncertainties regarding the success of subsequent clinical trials for innovative drugs and the potential for obtaining approval from the National Medical Products Administration [4] - The company emphasizes the importance of timely information disclosure regarding the progress of innovative drugs and encourages investors to make cautious decisions [4]

Core Viewpoint - Hainan Haiyao's new anti-epileptic drug, Paiengabin, is progressing rapidly in clinical trials, with its development being second only to Xenon's XEN1101 globally, indicating a significant opportunity in the anti-epileptic market due to unmet clinical needs and potential overseas value [1][3]. Group 1: Market Potential - The global epilepsy patient population is approximately 51.7 million, with around 9 million in China, highlighting a substantial market for anti-epileptic treatments [1]. - The Chinese anti-epileptic drug market has seen a compound annual growth rate of 2% over the past five years, with a market size of 5.3 billion RMB in 2023, and is expected to reach a scale in the hundred billion range [2]. Group 2: Drug Development and Advantages - Paiengabin, a new generation KCNQ2 channel agonist, shows significant improvements over the first-generation drug Retigabine, including better chemical stability, activity, and safety profile [3][4]. - Non-clinical and early clinical trials indicate that Paiengabin has superior efficacy, distribution, and safety compared to Retigabine, making it a promising option for patients with epilepsy [4]. Group 3: Clinical Progress and Competitive Landscape - Paiengabin is currently the fastest progressing KCNQ channel agonist in clinical trials in China, having successfully completed Phase IIa studies, while the global landscape shows limited competition with only a few candidates in development [5][6]. - The focus on developing effective and safer KCNQ2-targeted anti-epileptic drugs positions Hainan Haiyao favorably in a market with significant unmet needs [5]. Group 4: Strategic Transformation - Hainan Haiyao has adopted a strategy of combining generics with innovation, enhancing its R&D capabilities, and focusing on high-value innovative drugs to drive growth [7]. - The company's commitment to innovation and its robust pipeline are expected to facilitate its entry into the international pharmaceutical market, benefiting a larger patient population [7].

Meeting Details - The fourth extraordinary general meeting of shareholders was held on September 11, 2025, at 15:00 [1] - The meeting was conducted in a hybrid format combining on-site voting and online voting [2] - The meeting was presided over by independent director Ms. Hu Xiuqun due to the absence of the chairman [2] Attendance - A total of 275 shareholders participated, representing 408,289,551 shares, which accounts for 31.4707% of the total shares [3] - Among them, 1 shareholder attended the on-site meeting, representing 400,660,181 shares (30.8826%), while 274 shareholders voted online, representing 7,629,370 shares (0.5881%) [3][5] Resolutions - No resolutions were rejected during the meeting [4] - The meeting did not involve any changes to previous resolutions [4] Voting Results - The meeting approved the election of non-independent directors for the eleventh board of directors [8] - The candidates Mr. Pan Guihao and Ms. Zhang Ran were elected, with their terms starting from the approval date of the meeting [9] Legal Verification - The meeting was witnessed by lawyers from Beijing Dacheng (Haikou) Law Firm, who confirmed that the meeting complied with relevant laws and regulations [10]

证券代码：000566 证券简称：海南海药 公告编号：2025-057 海南海药股份有限公司 2025 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 二、会议召开的情况 1、会议召开的日期、时间： 现场会议召开时间：2025年9月11日下午15：00 网络投票时间：2025年9月11日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025年9月11日 9：15～9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为：2025年9月11日9:15～ 15:00期间的任意时间。 2、召开地点：海南省海口市秀英区南海大道 192 号海药工业园公司会议室 3、召开方式：采用现场表决与网络投票相结合的方式召开 1、参加现场会议和网络投票的股东 275 人，代表股份 408,289,551 股，占上市公司 总股份的 31.4707%。其中：参加现场会议的股东 1 人，代表有效 ...

北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第四次临时股东大会的 法 律 意 见 书 大成 is Dentons' Preferred Law Firm in China. 北京大成（海口）律师事务所 北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第四次临时股东大会 的法律意见书 致：海南海药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性文件的 要求，北京大成（海口）律师事务所（以下简称"本所"）接受海南海药股份有限 公司（以下简称"公司"）的委托，指派律师参加公司2025年第四次临时股东大 会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会所审议的 议案、议案所涉及的事项及内容发表意见。本所律师同意将本法律意见书随本次 股东大会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东 ...